国产精品欧美一区二区三区色欲,欧美日本日韩久久,国产午夜亚洲精品一区

人才隊(duì)伍

全體研究組長(zhǎng)

您當(dāng)前的位置 :

首頁(yè) > 人才隊(duì)伍 > 全體研究組長(zhǎng)

秦駿

博士

腫瘤細(xì)胞可塑性研究組組長(zhǎng)

郵箱: qinjun@sinh.ac.cn

電話(huà): +86-21-54923326

所屬部門(mén): 中國(guó)科學(xué)院腫瘤與微環(huán)境重點(diǎn)實(shí)驗(yàn)室

個(gè)人簡(jiǎn)歷

2017-至　今：中國(guó)科學(xué)院上海營(yíng)養(yǎng)與健康研究所，研究員
2014-2016年：中國(guó)科學(xué)院上海生命科學(xué)研究院/上海交通大學(xué)醫(yī)學(xué)院健康科學(xué)研究所研究員
2012-2014年：美國(guó)貝勒醫(yī)學(xué)院助理教授
2005-2012年：美國(guó)貝勒醫(yī)學(xué)院博士后
2000-2005年：中國(guó)科學(xué)院上海生命科學(xué)研究院生化與細(xì)胞所博士

研究方向

腫瘤細(xì)胞可塑性的表觀(guān)遺傳調(diào)控

研究?jī)?nèi)容

可塑性調(diào)控在藥物抵抗和腫瘤轉(zhuǎn)移中發(fā)揮著至關(guān)重要的作用，同時(shí)也是導(dǎo)致腫瘤異質(zhì)性的主要原因之一?？伤苄哉{(diào)控可被理解為細(xì)胞改變其身份的過(guò)程，包括同一譜系下細(xì)胞的分化，或者是細(xì)胞譜系的轉(zhuǎn)分化或去分化（例如，針對(duì)肺癌和前列腺癌的靶向治療導(dǎo)致下腺癌表型的轉(zhuǎn)變?yōu)樯窠?jīng)內(nèi)分泌腫瘤，以及干細(xì)胞的惡性轉(zhuǎn)化、腫瘤EMT和MET在腫瘤轉(zhuǎn)移過(guò)程中的動(dòng)態(tài)變化等）。進(jìn)一步可塑性調(diào)控也可擴(kuò)展至腫瘤整體表型的轉(zhuǎn)變，例如惰性腫瘤的進(jìn)展演化以及轉(zhuǎn)移過(guò)程中腫瘤的休眠和蘇醒等現(xiàn)象。
我們的研究以表觀(guān)遺傳調(diào)控與腫瘤細(xì)胞命運(yùn)決定及微環(huán)境重塑為核心，聚焦前列腺癌及腸癌診治中的臨床重大需求，探究表觀(guān)遺傳調(diào)控在腫瘤轉(zhuǎn)移及耐藥中的功能，并基于此提出潛在的治療策略；闡明表觀(guān)遺傳相關(guān)基因如何響應(yīng)藥物治療、代謝、炎癥等信號(hào)調(diào)控組蛋白修飾及染色質(zhì)重塑進(jìn)而決定腫瘤及微環(huán)境細(xì)胞的命運(yùn)及功能。

代表論著（#第一作者，*通訊作者）

Guo J#, Li N#,*, Liu Q#, Hao Z, Zhu G, Wang X, Wang H, Pan Q, Xu B, Han Y, Zhang G, Lian Y, Zhang W, Gu Y, Lin N, Zeng X, Jin Z, Lan W, Jiang J, Gao D, Dong L*, Yuan H*, Liang C*, Qin J*. KMT2C Deficiency Drives the Transdifferentiation of Double-Negative Prostate Cancer and Confer Resistance to AR-Targeted Therapy. Cancer Cell 2025;43(7):1261-1278
Zhu Q#, Zhang G#, Cao M#, Huang H#, He D, Xing J, Zhan M, Pei S, Deng X, Xu J, Zheng M, Liu C*, Qin J*, Xiao Y*. Microbiota-shaped neutrophil senescence imparts the sexual difference in bladder cancer. Nature Immunology 2025;26(5):722-736
Zhang G#, Lian Y#, Li Q#, Zhou S#, Zhang L, Chen L, Tang J, Liu H, Li N, Pan Q, Gu Y, Lin Nai, Wang H, Wang X, Guo J, Zhang W, Jin Z, Xu B, Su X*, Lin M*, Han Q*, Qin J*. Vagal pathway activation links chronic stress to decline in intestinal stem cell function. Cell Stem Cell 2025;32(5):778-794
Wang H#, Zhang S#, Pan Q#, Guo J, Li N, Chen L, Xu J, Zhou J, Gu Y, Wang X, Zhang G, Lian Y, Zhang W, Lin N, Jin Z, Zang Y, Lan W, Cheng X, Tan M, Chen F, Jiang J, Liu Q*, Zheng M*, Qin J*. Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer. Nature Cancer 2025;6(4):629-646
Teng M#, Guo J#, Xu X#, Ci X, Mo Y, Kohen Y, Ni Z, Chen S, Guo W, Bakht M, Ku S, Sigouros M, Luo W, Macarios CM, Xia Z, Chen M, Haq SU, Yang W, Berlin A, Kwast T, Ellis L, Zoubeidi A, Zheng G, Ming J, Wang Y, Cui H, Lok BH, Raught B, Beltran H*, Qin J*, He H*. Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation. Cancer Cell 2025;43(5):891-904
Dong B#, Xu J# *, Huang Y#, Guo J#, Dong Q#, Wang Y#, Li N, Liu Q, Zhang M, Pan Q, Wang H, Jiang J, Chen B, Shen D, Ma Y, Zhai L, Zhang J, Li J*, Xue W*, Tan M*, Qin J*. Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers. Nature Cancer 2024;5(9):1427-1447
Long X#, Zhang S#, Wang Y#, Chen J#, Lu Y#, Hou H#, Lin B#, Li Q, Shen C, Yang R, Zhu H, Cui R, Cao D, Chen G, Wang D, Chen Y, Zhai S, Zeng Z, Wu S, Lou M, Chen J, Zou J, Zheng M*, Qin J*, Wang X*. Targeting JMJD1C to selectively disrupt tumor Treg fitness enhances anti-tumor immunity. Nature Immunology 2024;25,525–536
Wang H#, Li N#, #, Liu Q#, Guo J, Pan Q, Cheng B, Xu J, Dong B, Yang G, Bin Yang B, Xuege Wang X, Gu Y, Zhang G, Lian Y, Zhang W, Zhang M, Li T, Zang Y, Tan M, Li Q, Wang W, Yu Z, Jiang J*, Huang H*, Qin J*. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell 2023;41,1345–1362
Chen M#, Wang K#, Han Y#, Yan S#, Yuan H, Liu Q, Li L, Li N, Zhu H, Lu D, Wang K, Fen Liu F, Luo D, Zhang Y, Jiang J, Li D, Zhang L, Ji H, Hu Zhou, Chen Y*, Qin J*, Gao D*. Identification of XAF1 as an endogenous AKT inhibitor. Cell Rep 2023;42(7):112690
Peng S#, Wang Z#, Tang P#, Wang S#, Huang Y, Xie Q, Wang Y, Tan X, Tang T, Yan X, Xu J, Lan W, Wang L, Zhang D, Wang B, Pan T, Qin J*, Jiang J*, Liu Q*. PHF8-GLUL axis in lipid deposition and tumor growth of clear cell renal cell carcinoma. Sci Adv 2023;9(31):eadf3566
Li N#, Liu Q#, Han Y#, Pei S#, Cheng B, Xu J, Miao X, Pan Q, Wang H, Guo J, Wang X, Zhang G, Lian Y, Zhang W, Zang Y, Tan M, Li Q, Wang X, Xiao Y, Hu G, Jiang J*, Huang H*, Qin J*. ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat Commun 2022;13(1):7281
Ren J#, Li N#, Pei S#, Lian Y, Li L, Peng Y, Liu Q, Guo J, Wang X, Han Y, Zhang G, Wang H, Li Y, Jiang J, Li Q, Tan M, Peng J, Hu G, Xiao Y, Li X*, Lin M*, Qin J*. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ-stimulated antitumor immunity. J Clin Invest 2022;132(8):e153167
Jia P#, Li X#, Wang X#, Yao L, Xu Y, Hu Y, Xu W, He Z, Zhao Q, Deng Y, Zang Y, Meiyu Zhang M, Zhang Y*, Qin J*, Lu W*. ZMYND8 mediated liquid condensates spatiotemporally decommission the latent super-enhancers during macrophage polarization. Nat Commun 2021;12,6535
Pan Q#, Zhong S#, Wang H#, Wang X, Li N, Li Y, Zhang G, Yuan H, Lian Y, Chen Q, Han Y, Guo J, Liu Q, Qiu T, Jiang J, Li Q, Tan M, Yin H, Peng J*, Xiao Y*, Qin J*. The ZMYND8-regulated Mevalonate Pathway Endows YAP-High Intestinal Cancer with Metabolic Vulnerability. Molecular Cell 2021;81(13):2736-2751
Qi X, Qiu J, Chang J, Ji Y, Yang Q, Cui G, Sun L, Chai Q, Qin J*, Qiu J*. Brg1 Restrains the Pro-Inflammatory Properties of ILC3s and Modulates Intestinal Immunity. Mucosal Immunol 2021;14(1):38-52
Yuan H#, Han Y#, Wang X#, Li N, Liu Q, Yin Y, Wang H, Pan L, Li L, Song K, Qiu T, Pan Q, Chen Q, Zhang G, Zang Y, Tan M, Zhang J, Li Q, Wang X*, Jiang J*, Qin J*. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways. Cancer Cell 2020 14;38(3):350-365
Yu T#, Gan S#, Zhu Q#, Dai D, Hou D, Wang Y, Pan Q, Xu J, Zhang X, Liu J, Pei S, Luo X, Peng C, Wu P, Romano S, Mao C, Huang M, Zhu X, Qin J*, Xiao Y*. Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. Nat Commun 2019;10(1):4353
Ding Y#, Li N #, Dong B#, Guo W, Wei H, Chen Q, Yuan H, Han Y, Chang H, Kan S, Wang X, Pan Q, Wu P, Peng C, Qiu T, Li Q, Gao D*, Xue W*, Qin J*. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest 2019;129(2):759-773
Chen J, Li N, Yin Y, Zheng N, Min M, Lin B, Zhang L, Long X, Zhang Y, Cai Z, Zhai S, Qin J*, Wang X*. Methyltransferase Nsd2 Ensures Germinal Center Selection by Promoting Adhesive Interactions between B Cells and Follicular Dendritic Cells. Cell Rep 2018 18;25(12):3393-3404
Zhang X, Wang Y, Yuan J, Li N, Pei S, Xu J, Luo X, Mao C, Liu J, Yu T, Gan S, Zheng Q, Liang Y, Guo W, Qiu J, Constantin G, Jin J, Qin J*, Xiao Y*. Macrophage/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3. J Exp Med 2018;215(5):1365-1382
Yuan H#, Li N#, Fu D#, Ren J, Hui J, Peng J, Liu Y, Qiu T, Jiang M, Pan Q, Han Y, Wang X, Li Q, Qin J*. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis. J Clin Invest 2017;127(9):3375-3391
Liu Y#, Peng J#, Sun T#, Li N, Zhang L, Ren J, Yuan H, Kan S, Pan Q, Li X, Ding Y, Jiang M, Cong X, Tan M, Ma Y, Fu D, Cai S, Xiaog Y, Wang X, Qin J*. Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNF?-mediated inflammation and apoptosis. Proc Natl Acad Sci U S A 2017;114(19):E3796-E3805
Li N#, Xue W#, Yuan H#, Dong B, Ding Y, Liu Y, Jiang M, Kan S, Sun T, Ren J, Pan Q, Li X, Zhang P, Hu G, Wang Y, Wang X, Li Q, Qin J*. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. J Clin Invest 2017;127(4):1284-1302

男女拍拍视频_手机无码在线观看_国产青青草X_www超碰com_懂色AV色吟AV夜夜嗨_夜夜撸日日干

人才隊(duì)伍

秦駿

個(gè)人簡(jiǎn)歷

研究方向

研究?jī)?nèi)容

代表論著（#第一作者，*通訊作者）

代表論著（#第一作者，*通訊作者）